All News
A new IA drug in OA 🚨
Cell therapy of apoptotic PBMCs ENX-CL-05-001
RCT Ph2A moderate to severe OA
134 pts 3 injections vs. PBO
Pain improvement 24%
Better response in people > 60 and more so 65yo
Potential improvement for > 6mo
Safety mainly local reactions to compound https://t.co/m2MZN3i22b
Aurelie Najm AurelieRheumo ( View Tweet)
Lung Ultrasound in CTD-ILD
Prospective cohort 146 pts CTD-ILD
30 preclinical ILD
76 limited ILD
40 extensive ILD
Median LUS scores higher if Extensive ILD
LUS scores correlation w/ fibrosis severity, DLCO & FCV
Agreement between LUS and HRCT severity 0.74
Excellent inter https://t.co/R9zGmCTT8Q
Aurelie Najm AurelieRheumo ( View Tweet)
Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO
Mos. 4-6: >10% improvement in alopecia w/Cenerimod
Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod
Early improvement in alopecia & ulcers w/Cenerimod
Promising?
#ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr
sheila RHEUMarampa ( View Tweet)
#ACRBest @RheumNow https://t.co/SP3tib5tL1
Aurelie Najm AurelieRheumo ( View Tweet)
52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA
Primary ACR 50 16wks
Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW
ACR50 50% 57% 51%
ACR70 36% 42% 42%
PASI100 55% 64% 58%
MDA 47% 52% 47%
No specific enthesitis data presented
No new safety signal
Next https://t.co/J18rSTmyze
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#2601 At single cell level using CyTOF, metabolic activity varied btw HC & autoimmune groups but clusters in At-Risk ANA+ve appeared closer to #SLE. ANA+ve who progressed to AI-CTD showed Plasmablast expansion & enhanced glycolysis. Could be used as target @RheumNow https://t.co/jtrM1wvQLk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What's new in sjogren's?
Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)
Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose
Similar rates of adverse events
@RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Gut microbiome on Urate metabolism study- 1500 men and women.
From 3 cohorts- Framingham, nurses health and men's lifestyle with blood and stool data
Focused on 5 urate metbolizing genes
Abst#2590 #ACR25 @RheumNow https://t.co/YxBb3WfcbB
Bella Mehta bella_mehta ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Is AI Smarter than a Doctor?
Dr. Janet Pope reviews key takeaways from the session, "Artificial Intelligence in Medical Education: From Theory to Practice," at #ACR25.
https://t.co/F6KEYAWi75 https://t.co/m57asdLGrn
Dr. John Cush RheumNow ( View Tweet)
#1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients. Each rise in PM2.5 significantly boosted DAS28, CDAI & joint counts.
Does cleaner air mean calmer joints?
@RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but that’s probably all the fraudulent hidden dexamethasone inside…
Beware+++
#ACR25 FDA Update @RheumNow https://t.co/rco4wTXBjO
David Liew drdavidliew ( View Tweet)
Making sense of machine learning. Key slides on Discriminative AI vs Generative AI. Liubov Arbeeva @RheumNow #ACR25 https://t.co/Xli1mSTVQf
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Dr. John Stone on IgG4RD
⬆️ common in males
⬆️internal organ involvement
🔸Mimics cancer
🔸Indolence makes it dangerous —-> organ complications
Diagnosis highly dependent on the rheumatologist based on clinical features, serologies, imaging & pathological data
#ACR25 @Rheumnow https://t.co/St4EbA7Dcj
sheila RHEUMarampa ( View Tweet)
US Electronic Health Record cohort 2000+pts
Incidence Heart Failure over 10 yrs 6.8%
HF asso w/
Older
Male
Lower eGFR
Hypertensive medication
Diabetes
TTMTS MTX, TNFi
Higher CRP
Probably surrogates for High Disease Activity...
How do we detect it?
Maybe not by using the https://t.co/s9SjEyk3WF
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too.
#ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4
David Liew drdavidliew ( View Tweet)
@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile
#ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB
Links:
David Liew drdavidliew ( View Tweet)
Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card.
We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better.
#ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW
David Liew drdavidliew ( View Tweet)
Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa
Richard Conway RichardPAConway ( View Tweet)
@US_FDA rheumatology approvals, 2025
#ACR25 @RheumNow https://t.co/uVLWqBx45m
David Liew drdavidliew ( View Tweet)
